Bluebird touts Zynteglo, Skysona launch progress as FDA decision on sickle cell therapy nears

After closing shop in Europe two years ago, bluebird bio still aims to become an industry-leading gene therapy maker in the U.S. But first, it’s hoping new launches will help keep its doors open over the next 12 months.